Condition: Alzheimer Disease · Mild Cognitive Impairment · Mild Dementia · Sponsor: Skane University Hospital
This research study aims to examine biomarkers of Alzheimer's disease (AD) as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Skåne University Hospital in Sweden. The study will enroll up to 600 cognitively healthy subjects aged 50 to 80 years with 3/4 having preclinical Alzheimer's disease. Recruitment and enrollment will be ongoing for 2-3 years, and subject participation will be lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure.
This description comes directly from the study's public registry record.
Erik Stomrud, MD, PhD · +46 40 33 10 00 · erik.stomrud@med.lu.se
Niklas Mattsson-Carlgren, MD, PhD · +46 40 33 10 00 · niklas.mattsson-carlgren@med.lu.se
Always discuss trial participation with your own doctor first.
| Skåne University Hospital | Malmö, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06121544